The implementation of personalized health care in cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers. Anaplastic lymphoma kinase (ALK), a tyrosine kinase, is a more recently characterized cancer biomarker in non-small-cell lung cancer (NSCLC). To identify NSCLC patients with ALK gene rearrangement in clinical trials, researchers have used the methods known as fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC)...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment